Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.
Nanobiotix (NBTX) ha pubblicato la sua ultima dichiarazione sui diritti di voto e sul capitale azionario al 31 dicembre 2024. L'azienda riporta 47.426.851 azioni in circolazione, con 49.204.910 diritti di voto teorici e 49.182.792 diritti di voto esercitabili.
Nanobiotix è un'azienda biotecnologica in fase avanzata, quotata sia su Euronext Paris che sul Nasdaq Global Select Market. L'azienda si concentra su approcci terapeutici basati sulla fisica e possiede più di 25 famiglie di brevetti su tre piattaforme di nanotecnologia: oncologia, biodisponibilità e biodistribuzione, e disturbi del sistema nervoso centrale.
Nanobiotix (NBTX) ha publicado su última declaración de derechos de voto y capital social a 31 de diciembre de 2024. La empresa informa 47.426.851 acciones en circulación, con 49.204.910 derechos de voto teóricos y 49.182.792 derechos de voto ejercitables.
Nanobiotix es una empresa de biotecnología en etapa avanzada que cotiza tanto en Euronext París como en el Nasdaq Global Select Market. La compañía se enfoca en enfoques terapéuticos basados en la física y posee más de 25 familias de patentes en tres plataformas de nanotecnología: oncología, biodisponibilidad y biodistribución, y trastornos del sistema nervioso central.
Nanobiotix (NBTX)는 2024년 12월 31일 기준으로 최신 투표권 및 자본금 보고서를 발표했습니다. 회사는 47,426,851 주식이 유통되고 있다고 보고하며, 49,204,910 이론적 투표권과 49,182,792 행사 가능한 투표권이 있다고 전했습니다.
Nanobiotix는 Euronext Paris와 Nasdaq Global Select Market에 모두 상장된 후기 단계 임상 생명공학 회사입니다. 이 회사는 물리학 기반의 치료 접근 방식에 집중하며, 25개 이상의 특허 가족을 세 가지 나노기술 플랫폼인 종양학, 생체이용률 및 생물분포, 그리고 중추신경계 질환에 걸쳐 보유하고 있습니다.
Nanobiotix (NBTX) a publié sa dernière déclaration sur les droits de vote et le capital social au 31 décembre 2024. La société rapporte 47.426.851 actions en circulation, avec 49.204.910 droits de vote théoriques et 49.182.792 droits de vote pouvant être exercés.
Nanobiotix est une entreprise de biotechnologie en phase avancée, cotée à la fois sur Euronext Paris et sur le Nasdaq Global Select Market. L'entreprise se concentre sur des approches thérapeutiques basées sur la physique et détient plus de 25 familles de brevets sur trois plateformes de nanotechnologie : oncologie, biodisponibilité et biodistribution, et troubles du système nerveux central.
Nanobiotix (NBTX) hat seine neueste Erklärung zu den Stimmrechten und dem Aktienkapital zum 31. Dezember 2024 veröffentlicht. Das Unternehmen berichtet von 47.426.851 ausgegebenen Aktien, mit 49.204.910 theoretischen Stimmrechten und 49.182.792 ausübbaren Stimmrechten.
Nanobiotix ist ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sowohl an der Euronext Paris als auch am Nasdaq Global Select Market notiert ist. Das Unternehmen konzentriert sich auf physikbasierte therapeutische Ansätze und besitzt mehr als 25 Patentfamilien auf drei Plattformen der Nanotechnologie: Onkologie, Bioverfügbarkeit und Biodistribution sowie Störungen des zentralen Nervensystems.
- Owns portfolio of over 25 patent families across three nanotechnology platforms
- Dual-listed on major exchanges (Euronext Paris and Nasdaq)
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE) --
Paris, France, January 9, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| December 31, 2024 | 47,426,851 | 49,204,910 | 49,182,792 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
FAQ
How many shares does Nanobiotix (NBTX) have outstanding as of December 31, 2024?
What is the difference between NBTX theoretical and exercisable voting rights?
How many patent families does Nanobiotix (NBTX) own?
On which stock exchanges is Nanobiotix (NBTX) listed?
